Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katja Werlenius

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Lakartidningen|May 27, 2014
[Questionable effect of antiviral therapy in malignant brain tumors]Sara Kinhult, Katja Werlenius, Anna-Lotta Hallbeck, et al.
Lakartidningen|August 28, 2014
[Inconclusive data]Sara Kinhult, Katja Werlenius, Anna-Lotta Hallbeck, et al.
Plos One|February 14, 2020
Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patientsKatja Werlenius, Boglarka Fekete, Malin Blomstrand, et al.
Clinical Neurology and Neurosurgery|October 7, 2018
Proton therapy for low-grade gliomas in adults: A systematic reviewErik Thurin, Petra W Nyström, Anja Smits, et al.
Journal of Neuro-Oncology|November 26, 2022
Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year periodCaroline Svenjeby, Louise Carstam, Katja Werlenius, et al.
Neoplasia (New York, N.Y.)|December 1, 2017
Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem CellsAnna Wenger, Katja Werlenius, Alexander Hallner, et al.
Journal of Neuro-Oncology|May 20, 2026
MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencingNathalie Skarin, Martin Hallbeck, Katja Werlenius, et al.
Frontiers in Oncology|February 14, 2025
Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hanne Blakstad, et al.
Neuro-Oncology Advances|November 12, 2021
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastomaKatja Werlenius, Giuseppe Stragliotto, Michael Strandeus, et al.
Frontiers in Oncology|May 25, 2026
Case Report: Proton beam therapy - friend or foe for patients with <i>IDH</i>-mutated WHO grade 2 and 3 gliomas?Liv Cathrine Heggebø, Lars Fredrik Fjæra, Frank Leonel Bello Garrote, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Lakartidningen|May 27, 2014
[Questionable effect of antiviral therapy in malignant brain tumors]Sara Kinhult, Katja Werlenius, Anna-Lotta Hallbeck, et al.
Lakartidningen|August 28, 2014
[Inconclusive data]Sara Kinhult, Katja Werlenius, Anna-Lotta Hallbeck, et al.
Plos One|February 14, 2020
Patterns of care and clinical outcome in assumed glioblastoma without tissue diagnosis: A population-based study of 131 consecutive patientsKatja Werlenius, Boglarka Fekete, Malin Blomstrand, et al.
Clinical Neurology and Neurosurgery|October 7, 2018
Proton therapy for low-grade gliomas in adults: A systematic reviewErik Thurin, Petra W Nyström, Anja Smits, et al.
Journal of Neuro-Oncology|November 26, 2022
Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year periodCaroline Svenjeby, Louise Carstam, Katja Werlenius, et al.
Neoplasia (New York, N.Y.)|December 1, 2017
Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem CellsAnna Wenger, Katja Werlenius, Alexander Hallner, et al.
Journal of Neuro-Oncology|May 20, 2026
MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencingNathalie Skarin, Martin Hallbeck, Katja Werlenius, et al.
Frontiers in Oncology|February 14, 2025
Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3Liv Cathrine Heggebø, Ida Maria Henriksen Borgen, Hanne Blakstad, et al.
Neuro-Oncology Advances|November 12, 2021
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastomaKatja Werlenius, Giuseppe Stragliotto, Michael Strandeus, et al.
Frontiers in Oncology|May 25, 2026
Case Report: Proton beam therapy - friend or foe for patients with <i>IDH</i>-mutated WHO grade 2 and 3 gliomas?Liv Cathrine Heggebø, Lars Fredrik Fjæra, Frank Leonel Bello Garrote, et al.
Pageof 2